The startup develops therapeutic compounds using a streamlined process that accelerates the transition of identified molecules from research to clinical trials. This approach addresses the lack of timely access to effective treatments for patients with limited therapeutic options.
Funding
$580K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of new therapies is often hindered by the challenge of effectively delivering therapeutic molecules to their intended target within the body. Overcoming biological barriers and ensuring efficient intracellular delivery remains a significant obstacle in translating research findings into clinical applications.
Solution
Diversa Technologies provides lipid nanoemulsion-based drug delivery systems designed to improve the biodistribution, stability, and intracellular delivery of a wide range of therapeutic molecules. Their patented technology allows for the encapsulation and delivery of small molecules, peptides, proteins, and nucleic acids, including mRNA. These nanoemulsions are biocompatible, stable in biological fluids, and can be customized to meet specific project requirements, facilitating the development of new nanomedicines for oncology, inflammatory diseases, and rare diseases. Diversa Technologies offers both ready-to-use kits and co-development services to accelerate the transition of therapeutic molecules from research to clinical trials.
Target Audience
Diversa Technologies serves pharmaceutical and biotechnology companies, as well as research institutions, seeking advanced drug delivery solutions to enhance the efficacy and translational potential of their therapeutic molecules.
Features
- Patented lipid nanoemulsion technology for versatile drug delivery
- High loading capacity for a wide range of molecules, including hydrophobic and amphiphilic compounds
- Demonstrated stability in various biological fluids, sera, and cell culture media
- Efficient intracellular delivery, overcoming biological barriers
- Customizable formulations for specific project needs
- Ready-to-use kits available for mRNA, peptides, proteins, and small molecules
- FluoGreen-labeled nanoparticles for cell tracking and internalization studies
- Scalable and replicable technology compatible with industrial and regulatory requirements